Navigation Links
Breast cancer risk varies among different progestins used in hormone replacement therapy
Date:8/10/2010

COLUMBIA, Mo. Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

"Synthetic progestins have different biological effects, due to differences in their structure, stability and how they interact in the body," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "Clinical use of progestins requires caution. These powerful steroids should only be prescribed when a person has no latent, or dormant, cancer and does not have a family history of cancer. However, it is difficult to diagnose latent tumor cells in women since there are no symptoms."

In the study, researchers compared the effects of four clinically relevant progestins on breast cancer tumors in an animal model. The progestins used in the study were the synthetic progestin medroxporgresterone acetate (MPA), norgesterel (N-EL), norethindrone (N-ONE) and megestrol acetate (MGA). In the United States, most women on hormone replacement therapy are treated with MPA, the progestin in Prempro, Hyder said.

"Although previous studies using an animal model for breast cancer found that MPA functions as a tumor promoter, this study show that N-EL and N-One, when administrated using the same protocol as used for MPA, strongly inhibited tumor development," Hyder said. "Thus progestins seem to have tumor-stage specific effects, which determine whether these will function as tumor promoters or tumor suppressors. Progestins, such as N-EL and N-ONE, may have potential as preventive agents in women with no history of breast disease or family history of breast cancer. These progestins may also have a preventive role in post-menopausal women who are at an increased risk for developing breast cancer due to ingestion of combined estrogen/progestin (MPA) hormone replacement therapy and may have early stage disease."

The chart below shows the tumor latency and tumor incidence for the four types of progestins. Tumor latency is the period from when the animal model is first exposed to tumor cells to the first signs of cancer.


'/>"/>

Contact: Steven Adams
adamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... ... After a long period of indulging in holidays, many individuals feel ready ... the detox categories, there is a rare yet successful way to cleanse the lungs ... Detox is an herbal-based formula designed to help cleanse people’s lungs from harmful chemicals ...
(Date:3/1/2017)... , ... March 01, 2017 , ... The Industrial Designers ... 5, 2017 by raising awareness of the profession of industrial design (ID) and relaunching ... content geared toward high school students and counselors; parents; and the greater public. , ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 2017 , ... Grund® America is proud to announce the new ... March 2017 International Housewares Show in Chicago (Grund Booth N6466). , “We are very ... quality,100% OEKO-TEX and GOTS Organic Cotton material. By adding the GOTS (Global Organic ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite ... colorectal cancer screening rates by supporting the 80% by 2018 initiative, led by ... and the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... , March 1, 2017  The Welch Foundation, ... for basic research, today announced that Drs. Neal ... are the 2017 recipients of the Norman Hackerman ... recognized as ,rising stars, having contributed significant scientific discoveries ... first time in the 15 years of the Hackerman ...
(Date:3/1/2017)... , Mar 01, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Acute ... clinical attributes of your competitor drugs and find out how the ...
(Date:3/1/2017)... stesso sistema sara, visibile nello stand a ECR, il Congresso Europeo di Radiologia ... la settima unità MROpen in Gran Bretagna, la prima in Galles. Il sistema ... Cardiff. ESC attualmente gestisce altri due sistemi di risonanza magnetica MROpen a Londra ... ... The open MRI scanner - ...
Breaking Medicine Technology: